Axon Enterprise Inc is building a public safety operating system by integrating a suite of hardware devices and cloud software solutions... Show more
Axon Enterprise operates an integrated public-safety platform spanning TASER energy weapons, body-worn and in-car cameras, cloud-based digital-evidence management, real-time operations tools, drones, and AI-assisted productivity software. This hardware-plus-software model is the core of its market positioning: connected devices generate a recurring, higher-margin software and services stream that deepens customer relationships and raises switching costs.
That structure supports meaningful medium-term expansion. Management has publicly articulated a goal of roughly $6 billion in annual revenue and about 28% adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) margins by 2028. The shift toward software is visible in the mix, with software and services growing at a faster rate than connected devices and an increasing share of software revenue now coming from offerings beyond core evidence management. A future contracted bookings figure above $15 billion also points to long-dated, multi-year revenue visibility.
Competitively, Axon benefits from a deeply embedded installed base and brand familiarity with law-enforcement agencies, which it is extending into corrections, federal agencies, enterprise security, and healthcare. Structural risks include competition from larger industrial-technology peers such as Motorola Solutions, ongoing scrutiny of AI and surveillance use in policing, and dependence on public-sector budget cycles.
Several forward-looking events could shape investor sentiment in the coming quarters. The most immediate is the company's upcoming earnings release, widely expected in early November 2026, when investors will focus on bookings momentum, ARR growth, body-camera shipment trends, and the trajectory of adjusted EBITDA margins.
Product-cycle catalysts include the continued ramp of the TASER 10 platform, broader deployment of Axon Body cameras, and accelerating adoption of the Dedrone counter-drone business, which recently surpassed $100 million in quarterly revenue. Federal contract momentum adds another layer: in October 2026, Axon disclosed new awards covering more than 22,000 body-worn cameras and evidence-management licenses, a Department of Homeland Security selection of the Dedrone platform, and Department of Veterans Affairs adoption of TASER 10 devices.
On the analyst front, the consensus recommendation profile remains constructive. Roughly 21 analysts tracked by major data providers hold a "Buy" or equivalent view, with an average price target near $690–$700. Recent activity has been mixed at the margin: firms such as TD Cowen and Barclays have maintained or reiterated bullish targets in the $675–$825 range, Argus Research raised its target, while others, including Raymond James, have trimmed targets amid valuation and margin considerations. Net-net, the consensus remains optimistic but increasingly selective about near-term execution.
Axon's trajectory is closely tied to several macro and industry dynamics. Public-sector budgets and grant funding influence law-enforcement procurement cycles, meaning municipal and federal fiscal conditions remain a demand variable. Technology-adoption trends are favorable: staffing shortages across law enforcement and corrections are pushing agencies toward automation and AI-assisted workflows, a structural tailwind for Axon's software and drone offerings.
At the same time, Axon is exposed to cost-side pressures. Management has flagged rising memory and component costs, supply-chain constraints, and tariff variability, which weighed on gross and operating margins in recent quarters and are expected to pressure third-quarter adjusted EBITDA before a seasonal fourth-quarter improvement. Interest rates and inflation also matter indirectly: higher financing costs can strain municipal budgets, while persistent input-cost inflation tests margin discipline. Geopolitically, the growth of counter-drone demand reflects a broader security-spending theme that Axon is positioned to serve.
Tickeron's Trend Prediction Engine is an AI-powered forecasting tool designed to help traders assess whether a stock, exchange-traded fund (ETF), or other asset may trend bullish, bearish, or sideways over the coming week or month. The engine is built to help users spot developing trends, evaluate possible breakouts or reversals, and compare predictions across a wide range of tradable instruments. It offers searchable prediction categories, historical context, and alert-oriented functionality to support timely decision-making. As part of a broader research process, tools like the Trend Prediction Engine can complement fundamental analysis when monitoring evolving price momentum in names such as AXON.
Looking toward 2026 and beyond, Axon's long-term story centers on the conversion of hardware customers into recurring software subscribers. With ARR growing near 40% and NRR above 125%, the company's expansion increasingly depends on deepening existing relationships rather than solely adding new logos. This recurring mix supports margin durability and revenue predictability, though near-term profitability remains sensitive to product ramp costs and input inflation.
Market-expansion opportunities are broadening: international markets, enterprise security, healthcare, corrections, and federal agencies all represent growth vectors beyond core domestic law enforcement. Technology transitions in AI and counter-drone systems are emerging as the next engines, with management signaling substantial year-over-year growth in both categories. Capital allocation will be an important theme to monitor, given a more complex capital structure and ongoing acquisitions.
Consensus expectations reflect confidence in sustained top-line growth, with analysts modeling roughly 30%+ revenue growth into the next fiscal year and meaningful multi-year earnings expansion. Competitive threats from established industrial-technology rivals, privacy and governance scrutiny of AI-driven surveillance, and potential dilution or cash demands from convertible financing remain the principal long-term risks. As always, price targets represent external analyst expectations rather than a company forecast.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, AXON has been loosely correlated with TECH. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if AXON jumps, then TECH could also see price increases.
| Ticker / NAME | Correlation To AXON | 1D Price Change % | ||
|---|---|---|---|---|
| AXON | 100% | +1.39% | ||
| TECH - AXON | 61% Loosely correlated | -0.10% | ||
| VCYT - AXON | 58% Loosely correlated | +4.11% | ||
| BEAM - AXON | 57% Loosely correlated | -2.08% | ||
| SEER - AXON | 56% Loosely correlated | N/A | ||
| ADPT - AXON | 56% Loosely correlated | +4.51% | ||
More | ||||
a clinical-stage biopharmaceutical company
Industry AerospaceDefense
The RSI Oscillator for AXON moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 27 similar instances when the indicator left oversold territory. In 23 of the 27 cases the stock moved higher. This puts the odds of a move higher at 85%.
The Moving Average Convergence Divergence (MACD) for AXON just turned positive on October 06, 2026. Looking at past instances where AXON's MACD turned positive, the stock continued to rise in 28 of 39 cases over the following month. The odds of a continued upward trend are 72%.
Following a +4.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where AXON advanced for three days, in 273 of 370 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
AXON may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AXON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
The Aroon Indicator for AXON entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 44 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. AXON’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 69 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AXON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 79, placing this stock better than average.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.294) is normal, around the industry mean (4.788). AXON has a moderately high P/E Ratio (170.190) as compared to the industry average of (16.638). Projected Growth (PEG Ratio) (1.949) is also within normal values, averaging (2.564). Dividend Yield (0.000) settles around the average of (0.060) among similar stocks. P/S Ratio (12.034) is also within normal values, averaging (18.330).